Sofosbuvir, Velpatasvir, And Voxilaprevir has 34 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rosuvastatin, Rosuvastatin Calcium, Carbamazepine. Patients taking Sofosbuvir, Velpatasvir, And Voxilaprevir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 34
- Contraindicated
- 2
- Major
- 10
- Moderate
- 3
Contraindicated (2)
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Rosuvastatin— Combination increases rosuvastatin exposure. Use with rosuvastatin tablets is not recommended.
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Rosuvastatin Calcium— Combination increases rosuvastatin exposure. Concomitant use is not recommended.
Major (10)
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Carbamazepine— P-gp inducer and moderate to strong CYP inducer that may significantly decrease plasma concentrations of sofosbuvir, vel…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Cyclosporine— OATP inhibitor that may substantially increase exposure of voxilaprevir. Coadministration is not recommended.
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Imatinib— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Irinotecan— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Lapatinib— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Methotrexate— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Mitoxantrone— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + St. John'S Wort— P-gp inducer and moderate to strong CYP inducer that may significantly decrease plasma concentrations of sofosbuvir, vel…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Sulfasalazine— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Topotecan— BCRP substrate whose exposure may be altered by velpatasvir and voxilaprevir inhibition. Coadministration is not recomme…
Moderate (3)
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Pitavastatin— pitavastatin ↑ pitavastatin Coadministration with VOSEVI may increase the concentration of pitavastatin and is not recom…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Pravastatin— HMG-CoA Reductase Inhibitors: pravastatin ↑ pravastatin Coadministration of VOSEVI with pravastatin has been shown to in…
- Sofosbuvir, Velpatasvir, And Voxilaprevir + Tenofovir— tenofovir disoproxil fumarate (tenofovir DF) ↑ tenofovir Monitor for tenofovir-associated adverse reactions in patients …